Skip to search formSkip to main contentSkip to account menu

XYOTAX

National Institutes of Health

Related topics

Related topics

1 relation

Broader (1)

paclitaxel poliglumex

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
2006
2006
Phase II study of xyotax (PPX) for androgen independent prostate cancer (AIPC).
14624 Background: PPX is a polymer conjugate of paclitaxel. In preclinical studies, PPX has an improved therapeutic profile… 
2006
2006
Tuft's report backs FDA fast-track, but post-marketing concerns loom
A new report from the Center for the Study of Drug Development at Tufts University in Boston, published in March, suggests that… 
2005
2005
Phase II study of paclitaxel poliglumex (PPX) /carboplatin (C) for 1st line induction and maintenance therapy of stage III/IV ovarian or primary peritoneal carcinoma
5012 Background: C/paclitaxel (P) treatment, with a 70% complete response rate based on CA 125, is standard induction therapy for… 
2005
2005
O-101 XYOTAX™/carboplatin vs paclitaxel/carboplatin for the treatmentof PS2 patients with chemotherapy-naïve advanced non-small cell lung cancer (NSCLC): The stellar 3 phase III study
2005
2005
Phase I evaluation of paclitaxel poliglumex (PPX) administered weekly for patients with advanced cancer
2043 Background: Weekly paclitaxel administration compared to Q3 week schedules may offer an efficacy benefit in patients with… 
2005
2005
Expediting Oncology Drug Approvals: The Public Backlash Against the FDA and Opportunities to Reform
The FDA has made great strides over the past twenty years in loosening drug approval regulations to speed important, life-saving… 
2005
2005
P-939 XYOTAX™ (paclitaxel poliglumex, PPX): Pharmacokineticevidence for prolonged tumor exposure and reduced systemic exposure to paclitaxel
Review
2004
Review
2004
Dilemmas in management: the controversial role of chemotherapy in PS 2 advanced NSCLC and the potential role of CT-2103 (Xyotax).
Platinum-based chemotherapy improves long-term survival in patients with advanced non-small cell lung cancer (NSCLC). Meta… 
Review
2004
Review
2004
CT-2103: a novel macromolecular taxane with potential advantages compared with conventional taxanes.
CT-2103 (Xyotax) is a polymer-drug conjugate designed to improve upon the therapeutic index and tolerability of conventional… 
Review
2004
Review
2004
CT-2103: emerging utility and therapy for solid tumours
CT-2103 (XYOTAX™, Cell Therapeutics, Inc.) is a conjugate of paclitaxel to a polyglutamate polymer. Its macromolecular nature… 
By clicking accept or continuing to use the site, you agree to the terms outlined in our Privacy Policy (opens in a new tab), Terms of Service (opens in a new tab), and Dataset License (opens in a new tab)